Efficacy of rapid IV administration of valproic acid for status epilepticus

Although not approved by the US Food and Drug Administration for the treatment of status epilepticus ( SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients ( 30 men) with SE treated with IV VPA (average dose, 31.5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration.